Evidence map›Paper›PMID 25884478›Full record

SynthesisWorld journal of surgical oncology2015

Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients.

Jimeng Hu, Hua Xu, Wenhui Zhu, Fei Wu, Jianqing Wang, Qiang Ding, Haowen Jiang

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04220398 naunknown statusnot on this mapstarted 2020, after this paper: background citation

A Prospective, Multicenter, Three-arm, Randomized, Controlled Study Comparing the Efficacy of Neoadjuvant Hormonal Therapy Combined With Systemic Chemotherapy (NCHT), Neoadjuvant Hormonal Therapy (NHT) and Radical Prostatectomy Only in Locally Advanced Prostate Cancer

TypeinterventionalSponsorRenJi HospitalRan2020 to 2024Enrolled475ConditionsProstate Cancer, Chemotherapy Effect, Hormone Sensitive Prostate Cancer, Locally Advanced Prostate CarcinomaArmsNeoadjuvant chemotherapy combined with hormone therapy, Neoadjuvant hormone therapy, Radical Prostatectomy (RP)+ extended lymph node dissection
NCT05917860 phase1active not recruitingnot on this mapstarted 2023, after this paper: background citation

Effect of Neoadjuvant Degarelix on MRI-guided Transurethral Ultrasound Ablation (TULSA) in Patients with Intermediate-risk Prostate Cancer: a Pilot Study

TypeinterventionalSponsorTurku University HospitalRan2023 to 2030Enrolled15ConditionsLocalized Prostate Carcinoma, Castration-Naive Prostate Cancer, Intermediate Risk Prostate Cancer, Prostate CancerArmsDegarelix, MRI-guided transurethral ultrasound ablation (TULSA)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jimeng HuDepartment of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. jimeng1214@126.com.
Hua XuDepartment of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. norman.xu@hotmail.com.
Wenhui ZhuDepartment of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. 12211220025@fudan.edu.cn.
Fei WuDepartment of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. uro_wf@163.com.
Jianqing WangDepartment of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. wjq-077@163.com.
Qiang DingDepartment of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. dingqiang_uro@126.com.
Haowen JiangDepartment of Urology, Huashan Hospital, Fudan University, No.12 WuLuMuQi Middle Road, 200040, Shanghai, People's Republic of China. haowenj73@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeo-adjuvant hormone therapy (NHT) following radical prostatectomy (RP) or radiotherapy has been utilized in the multimodal approach to patients with intermediate- to high-risk prostate cancer (PCa). Herein, we performed a systematic review and meta-analysis of published randomized trials to evaluate the clinical efficacy of NHT.

methodsLiteratures were searched from PubMed, EMBASE, Web of Science, and Cochrane Library for comparing neo-adjuvant therapy group (NHT plus radiotherapy or radical prostatectomy) with traditional therapy (radiotherapy or prostatectomy) alone. Quality of the research was assessed on the basis of the Cochrane's risk of bias of randomized controlled trial. Comparable information were obtained from eligible trials and assembled for meta-analysis up to 31 August 2014. RevMan 5.2 software was used for statistical analysis.

resultsFifteen randomized controlled trials (RCTs) (total 5,194 patients) were included in this study. Meta-analysis showed there was a significant improvement in overall survival (OS) (Odds ratio (OR) = 1.51, 95% confidence interval (CI) 1.22 to 1.87, P = 0.0002), positive surgical margin (PSM) rate (OR = 0.30, 95% CI 0.24 to 0.38, P < 0.00001), and biochemical disease-free survival (bDFS) (OR = 1.95, 95% CI 1.13 to 3.39, P = 0.02), but no significant difference in disease-free survival (OR = 1.52, 95% CI 0.90 to 2.59, P = 0.12) and clinical disease-free survival (cDFS) (OR = 0.96, 95% CI 0.22 to 4.18, P = 0.95). Heterogeneity and risk of bias were observed between different studies.

conclusionsPatients with aggressive prostate cancer would better benefit from the receipt of neo-adjuvant therapy. Physicians should make individualized treatment strategies according to adverse reactions, financial capacities, and personal wishes.

Indexed as

Neoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantHumansMalePrognosisProstatic NeoplasmsRandomized Controlled Trials as Topic

Identifiers

PMID25884478
PMCPMC4344800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.